Drew Thieme
About Drew Thieme
Drew Thieme is a cheminformatician with a PhD in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill, specializing in computational chemistry, psychopharmacology, and drug discovery.
Title: Cheminformatician
Drew Thieme holds the title of Cheminformatician. This role encompasses various scientific disciplines and involves the application of informatic techniques to chemistry-related problems. It requires a deep understanding of both chemistry and data analysis to drive advancements in drug discovery and development.
Education: PhD in Pharmaceutical Sciences
Drew Thieme earned a PhD in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill. His doctoral research was centered on harmonizing raw subjective scent data through natural language processing and predicting scent perception profiles based on chemical structures. This advanced training developed his expertise in multiple domains of pharmaceutical sciences and cheminformatics.
Education: Bachelor's Degree from Purdue University
Drew Thieme holds a Bachelor's Degree in Pharmaceutical Sciences from Purdue University. This foundational education provided him with comprehensive knowledge in pharmaceutical sciences, forming the basis for his advanced studies and subsequent research in cheminformatics and drug discovery.
Expertise in Data Science and Computational Chemistry
Drew Thieme is an expert in various interconnected fields, including data science, computational chemistry, medicinal chemistry, psychopharmacology, pathophysiology, and drug discovery and development. His work integrates machine learning, quantitative structure-activity relationship modeling, molecular modeling, and biomedical knowledge graph analysis to innovate drug discovery processes and therapeutic interventions.
Innovative Research in Scent Data and Drug Action
During his PhD, Drew Thieme's dissertation focused on harmonizing and predicting subjective scent data using natural language processing. Additionally, he contributed to the development of the Clinical Outcomes Pathways, which aims to better classify and compare drug actions. His work is extending into the domain of subjective psychedelic experiences to facilitate the discovery of novel psychedelic compounds and the precision design of altered states at Mindstate Design Labs.